Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder, which affects 20 to 30 million individuals worldwide. Currently, no effective therapies to treat or cure this disease have been developed. As a leading provider of custom mouse and rat models, Cyagen aims to support the advancement of Alzheimer's disease (AD) research with our expertise.
Herein, we have collected all our resources and support materials related to Alzheimer's disease (AD) research.
Gene therapy is emerging as a powerful therapeutic tool to treat – and even prevent - Alzheimer's disease (AD). In the past few decades, gene therapy has made significant progress in the treatment of Alzheimer's disease (AD). In practice, scientists apply genomic and proteomic methods to identify the disease-causing gene, subsequently verifying the target gene with in vitro and in vivo experiments. With this methodology, scientists have published many high-impact gene therapy research articles.
Cyagen has aimed to support Alzheimer's disease (AD) studies in a variety of ways. Our services enable the development of therapeutics for Alzheimer's disease (AD) by delivering genotype-guaranteed animal models to study disease mechanisms, target validation, drug screening and more.
The predominant animal models currently used in the research of Alzheimer's disease (AD) are genetically modified mice. Although promising results have been achieved in this field, almost all corresponding clinical trials have failed, especially with regards to drug development centered on the amyloid hypothesis. In light of this, it may be time to reconsider the model selected for the research of AD drug development from a new perspective. Although rats have been largely overlooked in recent decades, the limitations of mice have pushed rat models into the spotlight for AD research, largely due to the following points:
To support the research of Alzheimer's disease (AD), our recent ‘Weekly Gene’ articles have focused on specific genes linked to the pathogenesis of Alzheimer's disease (AD). In these articles, we review the functionality of specific gene targets, explore their pathogenic role in Alzheimer's disease (AD), discuss related therapeutic progress, and more.
RPS23RG1-mediated Stabilization of Synaptic Function Rescues AD-Associated Cognitive Deficits
In under 15 years, Cyagen has become a leading provider of custom mouse and rat models – delivering over 78,400 models to researchers worldwide and receiving over 4,750 peer-reviewed citations. Cyagen prides itself on its premium customer service: including price-matching, client access to complimentary technical consultations, full confidentiality, and a 100% money-back service guarantee.
1. Complete research solutions – from custom rodent model generation to therapeutic viral packaging and injection.
2. Both in vivo (animal) and in vitro (cell) experimental models available
3. Expert scientific team provides in-depth technical support in formulating research model strategies.
From strategy design through to delivery of research-ready custom models, Cyagen offers complete outsourcing for all your animal model needs. We can create any custom mouse or rat model with guaranteed genotype validation, even offering phenotypic characterization and other downstream services required to establish a rare disease model.
Contact us with your project details to request your complimentary model generation project consultation, strategy, and quote.